New Scientific Article in Nature Linking the Potential Use of NeuroRestore ACD856 for the Treament of Obesity

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced today that an article has been published in Nature suggesting the use of NeuroRestore ACD856 in the treatment of obesity.

The article, entitled Missense variants in FRS3 affect body mass index in populations of diverse ancestries, was published in the prestigous journal Nature by Andrea Jonsdottir & Kari Stefansson et al. The authors found FRS3 to be a convincing downstream component of the BDNF-TrkB pathway, which could potentially be targeted for obesity treatment. The authors also reference NeuroRestore ACD856 several times, e.g.:

• “The recent synthesis of an intracellular positive modulator of central Trk-signaling presents an opportunity for targeting TrkB or its downstream proteins, including FRS3.“
• “This molecule therefore raises the prospect of targeting the BDNF-TrkB pathway in treatment of obesity.”

Indeed, BDNF is believed to play an essential role in maintaining a healthy weight by suppressing appetite, enhancing metabolism, and preventing excessive fat storage. Low BDNF levels are associated with obesity and metabolic disorders, while increasing BDNF may help regulate body weight. Human genetics related to the BDNF gene (e.g. Val66Met polymorphism) are also linked to a higher risk of obesity.

Another article, also published in Nature and entitled Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling by Claire Feetham & Simon Luckman et al., show that BDNF neurons are required for the weight-reducing actions of GLP1 receptor agonists. This would indicate that the use of a compound such as NeuroRestore ACD856, which enhances BDNF/TrkB signaling might provide a route for longer-term weight loss and could be used as a standalone treatment or in combination with GLP1 receptor agonists such as Wegovy and Zepbound to synergistically enhance its effects even further.

These are new and highly interesting results that implicate the use of NeuroRestore ACD856 for use in the treatment of obesity. Of special interest is the potential use of it in combination with GLP1 agonists to further enhance the weight-reducing effects. Indeed, previous studies with ACD856 have shown effects in obese animals e.g. increased insulin sensitivity. We are monitoring this area with great interest, including with regard to clinical trials"

Martin Jönsson, CEO, AlzeCure Pharma AB